CraniSeal Dural Sealant
Pramand, LLC · Decision date Jul 6, 2023
What did the FDA approve?
FDA approved the CraniSeal Dural Sealant from Pramand, LLC on July 6, 2023. The device is indicated for patients 18 years of age and older as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.
The approval is an original PMA under product code NQR in the dural sealant category. The source statement reports the intended use but does not include clinical data, safety findings, or effectiveness endpoints. No supplement type or reason is listed, so no relationship to a prior PMA is established.
FDA approval order statement
Approval for the CraniSeal Dural Sealant. The device is indicated for use in patients >= 18 years of age as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Jul 6, 2023
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220014
- Regulatory pathway
- Premarket approval application
- Applicant
- Pramand, LLC
- Product code
- NQR
- Decision code
- APPR
- Decision date
- Jul 6, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sealant, dural.
- Applicant
- Pramand, LLC
- Product code
- NQR
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220014 received
Application receipt date recorded by FDA.
P220014 · FDA decision
APPR
P220014/S013 · Related supplement
CraniSeal Dural Sealant
Timeline entries are records held by MedtechLedger for P220014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CraniSeal Dural SealantP220014/S013 | Pramand, LLC | PMA supplement | Oct 1, 2026 | FDA |
Explore the linked device profile
Other records with product code NQR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SpineSeal Spine SealantP240027/S007 | Pramand, LLC | PMA supplement | Sep 11, 2026 | FDA |
SpineSeal Spine SealantP240027 | Pramand, LLC | PMA approval | Feb 14, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Pramand, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., Suite 210, Bedford, MA, 01730
Sources and methodology
- Original FDA record: P220014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

